Focus & Cognition

Also known as: Provigil, Alertec, Modalert, Modvigil, Modawake, 2-((diphenylmethyl)sulfinyl)acetamide, CRL-40476

Modafinil is a prescription wakefulness-promoting agent approved by the US Food and Drug Administration in December 1998 under the brand name Provigil (Cephalon, now Teva) for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and as an adjunct to continuous positive airway pressure therapy in obstructive sleep apnea. It is a racemic mixture of R- and S-enantiomers; the R-enantiomer (armodafinil, brand name Nuvigil) was approved separately in 2007 as a longer-acting alternative. Modafinil became a Schedule IV controlled substance in the United States in 1999, reflecting a low but non-zero abuse potential that is substantially below that of amphetamines and classical stimulants. The compound is structurally unrelated to amphetamines, methylphenidate, and other stimulant classes — it is a diphenylmethylsulfinyl acetamide with a distinct pharmacology that produces wakefulness and cognitive effects without the catecholamine surge, appetite suppression, and cardiovascular profile of traditional stimulants. Modafinil's approved medical use base is narrow, but its off-label use is enormous. Physicians prescribe it off-label for ADHD (particularly in patients who do not tolerate or respond to stimulants), fatigue in multiple sclerosis and other neurologic conditions, cancer-related fatigue, depression augmentation (particularly for residual fatigue and cognitive symptoms), post-concussion cognitive dysfunction, jet lag, and age-related cognitive decline. Off-label and non-medical use as a cognitive enhancer — among students preparing for exams, professionals working long hours, military personnel during sustained operations, and the general nootropic community — has made modafinil one of the most-discussed cognitive enhancement compounds in both academic and lay media. The evidence base is substantial for approved indications and mixed for off-label use, with meta-analyses and systematic reviews documenting meaningful cognitive benefits in sleep-deprived users and healthy users performing complex cognitive tasks, alongside more modest or inconsistent effects on simple cognitive measures in rested users. Its safety profile across 25+ years of clinical use is generally favorable, though rare serious adverse events including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) require specific attention. This entry covers modafinil's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives wakefulness; the clinical evidence base for approved indications including narcolepsy, shift work disorder, and OSA; the off-label cognitive enhancement literature with its well-known heterogeneity between sleep-deprived and rested subjects; the side effect profile including common, serious, and rare adverse effects; the practical dosing conventions used in medical and non-medical contexts; its interactions with hormonal contraception and CYP450 substrates; contraindications based on cardiovascular, hepatic, and psychiatric history; how modafinil compares to and stacks with other nootropic compounds like Noopept, Piracetam, Sulbutiamine, Bromantane, Selank, Semax, Methylene Blue, NAD+, L-Theanine, and L-Tyrosine; and what responsible use looks like for someone considering modafinil for either medical or cognitive enhancement purposes. Modafinil remains the single most clinically validated cognitive enhancement compound available, with a body of evidence, safety data, and regulatory oversight that no research-chemical nootropic can match. For users who need demonstrably effective wakefulness promotion for legitimate medical reasons, it is a first-line option. For users considering it for cognitive enhancement, it is a serious drug with real effects and real side effects that deserves a serious evaluation rather than casual experimentation.

Also known as: 1,3,7-trimethylxanthine, Methyltheobromine, Trimethylxanthine, Theine, Guaranine, Mateine, Caffeine anhydrous, Caffeine citrate

Caffeine (1,3,7-trimethylxanthine) is a natural methylxanthine alkaloid found in the seeds, fruits, leaves, and bark of over 60 plant species — most notably Coffea (coffee), Camellia sinensis (tea), Theobroma cacao (cacao), Paullinia cupana (guaraná), Ilex paraguariensis (yerba mate), and Cola acuminata (kola nut). It is the world's most widely consumed psychoactive substance, with an estimated 80-90% of the global adult population consuming caffeine regularly — primarily through coffee, tea, cocoa, soft drinks, and energy drinks. Caffeine is the reference compound in pharmacology for adenosine receptor antagonism and one of the most comprehensively studied drugs in human history, with over 50,000 published studies covering its pharmacokinetics, pharmacodynamics, cognitive effects, cardiovascular impact, exercise performance, sleep effects, metabolic effects, addiction profile, and clinical applications. Pharmacologically, caffeine is a non-selective adenosine receptor antagonist — it binds and blocks adenosine A1, A2A, A2B, and A3 receptors throughout the body, with particularly important effects in the central nervous system (A1 and A2A antagonism in striatum, cortex, and sleep-regulating nuclei), heart (A1 antagonism contributing to mild tachycardia), adipose tissue (A1 antagonism promoting lipolysis), and airways (A2B antagonism contributing to mild bronchodilation). Adenosine is an endogenous signaling molecule that accumulates during wakefulness and neural activity, promoting sleepiness and reducing arousal through these receptor systems — caffeine works by blocking adenosine's sleep-promoting and fatigue-signaling effects, producing the familiar alerting, arousal, and performance-improving effects. Beyond adenosine receptor antagonism, caffeine at higher doses (typically >500mg) has additional pharmacologic actions: phosphodiesterase inhibition (modest), intracellular calcium mobilization via ryanodine receptors, and GABA-A receptor modulation — but these higher-dose mechanisms are not primary at typical consumption levels. Caffeine pharmacokinetics are remarkably variable between individuals, primarily reflecting genetic variation in the hepatic cytochrome P450 enzyme CYP1A2, which metabolizes ~95% of ingested caffeine. The **CYP1A2*1F polymorphism (rs762551) divides the population into "fast metabolizers" (AA genotype, ~40% of caffeine more rapidly cleared) and "slow metabolizers" (CC genotype, substantially slower clearance), with heterozygotes (AC) intermediate. This genetic variation produces notable differences in plasma half-life: 3-5 hours in fast metabolizers, 5-8 hours in intermediates, and up to 10-15 hours in slow metabolizers. The same 200mg caffeine dose can produce very different durations of effect — and very different sleep impacts from afternoon coffee — depending on CYP1A2 genotype. Additional modulators: oral contraceptives reduce caffeine clearance by ~40% (effectively doubling half-life), pregnancy reduces clearance by 50-60% in third trimester, smoking induces CYP1A2 and increases clearance by 30-50% (so smokers often report paradoxically shorter caffeine effects), liver disease prolongs half-life, and various medications (fluvoxamine, ciprofloxacin, cimetidine) inhibit CYP1A2 and prolong caffeine effects substantially. Understanding one's own caffeine pharmacokinetics — through genetic testing, self-observation of sleep effects from afternoon caffeine, and awareness of life-stage changes — is key to optimal caffeine use. Clinical applications and evidence base span notable breadth: (1) Cognitive performance and alertness — caffeine 40-200mg reliably improves reaction time, sustained attention, vigilance, and cognitive performance under fatigue (Smith 2002 meta-analysis, Lorist & Tops 2003). (2) Exercise performance — caffeine 3-6 mg/kg ingested ~60 minutes before exercise reliably improves endurance performance by 2-5% (Grgic et al. 2020 umbrella review), improves muscular endurance and some aspects of power output, and is classified by WADA as monitored but not banned at current consumption levels (though it was banned 1984-2004). (3) Headache treatment — caffeine potentiates analgesic effects of acetaminophen and aspirin (the basis for combinations like Excedrin); is first-line for post-dural puncture headache at IV doses; and improves many tension and migraine headaches. (4) Neonatal apnea of prematurity — IV caffeine citrate is standard-of-care treatment, with the landmark CAP trial (Schmidt 2006, 2012) establishing long-term developmental benefits. (5) Asthma and respiratory conditions — caffeine has mild bronchodilator effects; not a replacement for β2-agonists but some supplementary role. (6) Weight management — caffeine modestly increases energy expenditure and fat oxidation, though weight loss effects of caffeine alone are clinically modest. (7) Parkinson disease prevention — strong epidemiological evidence (Ross 2000, Palacios 2012) that lifetime coffee/caffeine consumption is associated with reduced Parkinson disease risk. (8) Type 2 diabetes prevention — strong epidemiology (van Dam 2002, 2006) associating coffee consumption with reduced diabetes risk (effect may involve components beyond caffeine). (9) Hepatoprotection — coffee/caffeine consumption associated with reduced liver cirrhosis, reduced hepatocellular carcinoma, reduced NAFLD progression. Caffeine is simultaneously one of the safest and most problematic drugs in common use. Safe at typical consumption levels (≤400mg/day for most adults per EFSA/FDA), it produces tolerance, dependence, and withdrawal syndrome with regular use — the characteristic "caffeine withdrawal headache," fatigue, and reduced cognitive performance on cessation are well-documented (Juliano & Griffiths 2004 meta-analysis established caffeine withdrawal as a clinically-defined syndrome with DSM-5 inclusion). Tolerance to many caffeine effects develops over 1-2 weeks of regular use, though tolerance is incomplete and most chronic users still derive significant alertness and performance benefits. At high doses (>500mg), caffeine produces anxiety, tachycardia, tremor, insomnia, and GI distress; at very high doses (>5-10g), caffeine is potentially lethal — fatal caffeine toxicity** has occurred primarily from concentrated caffeine powder overdoses (FDA-issued warnings 2014) or severe energy drink overconsumption combined with pre-existing cardiac conditions. Individual sensitivity varies enormously; some individuals experience significant anxiety at 50mg while others tolerate 400mg without obvious effects. See also L-Theanine, Adenosine, Theacrine, Yerba Mate, Green Tea Extract, Alpha-GPC, CDP-Choline, and Tyrosine for adjacent nootropic, alertness, and attention-support compounds. This is educational content, not medical advice — caffeine use intersects with many health conditions, medications, and life stages (pregnancy, certain cardiovascular conditions, anxiety disorders, sleep disorders) where individualized guidance matters.

Also known as: ACTH 4-10, BDNF Spray, BDNF, Flow Spray

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, 813 Da molecular weight) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The compound is derived from ACTH(4-10) — the 4-10 amino acid fragment of adrenocorticotropic hormone — with the addition of a Pro-Gly-Pro C-terminal tail that confers resistance to enzymatic degradation while preserving neurotropic activity. Critically, Semax retains the cognitive, neurotrophic, and neuroprotective effects of its ACTH parent while completely lacking the adrenal-stimulating hormonal activity. In other words, Semax works on the brain without activating the HPA axis or affecting cortisol production — a therapeutically ideal profile. Semax was patented in 1982 by Russian researchers and achieved regulatory approval in the Russian Federation in 2000, where it is prescribed at pharmacies for cerebrovascular disorders (ischemic stroke recovery), optic nerve disorders, minimal brain dysfunction in children (ADHD-like presentations), asthenia, and various cognitive complaints. It is available in two commercial strengths: 0.1% intranasal solution for cognitive-nootropic indications and 1% intranasal solution for stroke recovery and neurological deficits. In Western markets, Semax has never been submitted for FDA, EMA, or other major regulatory approval — a pattern common to Russian neuropeptides that lack patent protection and Western pharmaceutical sponsors. It circulates in US and European biohacking communities through research chemical peptide suppliers and is considered one of the most potent, best-tolerated nootropic compounds available. The pharmacology of Semax is genuinely notable and spans multiple neurological domains. At the molecular level, Semax elevates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the brain, promotes dopaminergic and serotonergic signaling, potentiates endogenous enkephalin activity, and upregulates expression of neuroprotective genes. At the clinical level, it produces cognitive enhancement (attention, memory, executive function), mood elevation, stress tolerance, neuroprotection during ischemia, and accelerated recovery from neurological injury. Russian clinical trials in acute ischemic stroke — the best-documented Semax indication — show meaningful improvements in functional recovery when Semax is administered within 6-24 hours of stroke onset, likely through direct neuroprotection plus enhanced neurogenesis during recovery. The stroke literature is the only domain where Semax has truly rigorous clinical trial evidence (Gusev et al., 2005). In the biohacking and cognitive enhancement community, Semax has achieved a reputation as the "premier Russian nootropic" — often positioned alongside Selank, Noopept, Modafinil, and racetams in the advanced cognitive stack. Users typically report improvements in focus, working memory, verbal fluency, motivation, stress tolerance, and overall cognitive throughput. The effects are often described as "clean" — producing alertness and engagement without the jitters of stimulants, without the emotional blunting of SSRIs, and without the sedation of anxiolytics. Dose-response is relatively modest (300-900 mcg daily typical), onset is rapid (15-30 minutes after intranasal administration), and effects last several hours per dose. Chronic use over weeks produces accumulating cognitive and mood benefits that appear to outlast plasma presence. This entry covers Semax pharmacology, the genuinely rigorous Russian stroke evidence base, the more speculative cognitive enhancement applications, protocol considerations, and safety profile. It should be read as an educational reference — Semax is not FDA-approved, is distributed through gray-market channels with variable quality, and anyone considering use should obtain reliable product, start conservatively, and have realistic expectations. Cross-reference with Selank, DSIP, and Epithalon for Russian peptide context, and with Noopept, Piracetam, and Modafinil for broader nootropic comparisons.

Also known as: NASA-Semax, N-Acetyl Semax

Acetylated form of Semax peptide with improved stability and potency, used as a nasal spray for cognitive enhancement and neuroprotection.

Also known as: TP-7, Selank Spray

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility. Selank adds a Pro-Gly-Pro tail to the tuftsin sequence, which confers resistance to enzymatic degradation while preserving pharmacological activity. In Russia, Selank has been approved since 2004 for the treatment of generalized anxiety disorder (GAD) and is available by prescription at pharmacies across the Russian Federation and several neighboring countries. It is marketed as a 0.15% intranasal solution under the brand name "Selank" (╨í╨╡╨╗╨░╨╜╨║) by Peptogen, a Moscow-based pharmaceutical company. In Western markets, Selank has never been submitted for FDA, EMA, or other major regulatory approval — not because of unfavorable data, but because the commercial pharmaceutical industry has no mechanism to profit from a peptide with an expired patent and no Western development sponsor. As a result, Selank circulates in the biohacking and peptide-curious community primarily as a "research chemical" through specialty peptide suppliers, where it is sold in intranasal spray or injectable formulations. The pharmacological profile of Selank is distinctive among anxiolytics. Unlike benzodiazepines, it does NOT cause sedation, cognitive dulling, tolerance, dependence, or withdrawal. Unlike SSRIs, it has rapid onset (within 30-60 minutes of intranasal administration) and effects that outlast plasma presence. Unlike buspirone, it does not require weeks of chronic dosing to manifest effects. The compound appears to work through modulation of multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and endogenous opioid — producing what the Russian clinical literature describes as an "anxiolytic + nootropic" profile: the user feels calmer but also more mentally engaged, not sedated. This unusual combination has driven substantial interest in Western biohacking circles as an alternative or adjunct to conventional anxiety pharmacology. Selank has been studied in Russian clinical populations for over two decades with a consistent efficacy and safety pattern across roughly 30-50 published clinical papers. The evidence base is real but has important limitations: most trials are Russian-language, published in Russian journals, with small sample sizes (often 30-100 patients), and use Russian psychiatric rating scales rather than the validated Western instruments (GAD-7, HAM-A, Beck Anxiety Inventory) that would facilitate cross-validation. Western meta-analyses and systematic reviews are essentially nonexistent. The Russian regulatory approval is real and meaningful — Russian drug regulation, while different from FDA standards, does require efficacy and safety evidence — but it does not automatically translate to confidence in Western evidence-based medicine frameworks. For the biohacking community, Selank's appeal is the combination of (1) rapid-acting anxiolysis without sedation, (2) cognitive enhancement rather than dulling, (3) favorable safety profile across decades of Russian use, (4) non-addictive, non-dependence-producing pharmacology, and (5) intranasal delivery that is simple and needle-free. Its limitations are (1) thin Western evidence base, (2) variable quality from research chemical suppliers, (3) lack of FDA regulation or oversight, (4) modest effect magnitude in some users relative to expectations, and (5) cost relative to generic anxiety pharmacology. This entry covers the pharmacology, clinical evidence, practical use considerations, and honest framing of the evidence gaps. Cross-reference with Semax, DSIP, and Epithalon for a complete picture of the Russian research peptide landscape.

Also known as: NASA-Selank, N-Acetyl Selank

Acetylated form of Selank peptide with enhanced bioavailability, commonly used as a nasal spray for anxiolytic and nootropic effects.

Also known as: Semax Selank

Combined nootropic and anxiolytic peptide blend

Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. Chemically it is N-(2-adamantyl)-N-(para-bromophenyl)amine, an adamantane derivative structurally related to amantadine and memantine but pharmacologically distinct from both. What makes Bromantane unusual and clinically interesting is that it acts simultaneously as a mild dopamine reuptake inhibitor and as an activator of tyrosine hydroxylase and aromatic L-amino acid decarboxylase gene expression in mesolimbic and mesocortical dopamine neurons, producing a gentle upregulation of endogenous dopamine synthesis rather than the forceful synaptic dopamine release characteristic of amphetamines or methylphenidate; alongside this dopaminergic effect it promotes neurosteroid synthesis particularly of allopregnanolone and related GABA-A positive modulators, which is thought to underlie its anxiolytic rather than anxiogenic profile and distinguishes it from conventional stimulants that typically produce dose-dependent anxiety. The clinical positioning in Russia has been for neurasthenia, asthenic depression, chronic fatigue states, post-infectious fatigue, and adaptation support during physical and cognitive stress, with multiple placebo-controlled and active-comparator trials published in Russian and occasionally English literature reporting benefits across fatigue, attention, mood, and sleep quality scales at daily doses typically in the 50-100 mg range for 2-6 week courses. Outside Russia Bromantane has never been approved for clinical use, is not controlled under most Western drug schedules because it predates modern scheduling and does not fit amphetamine or modafinil frameworks cleanly, and circulates primarily as a research chemical or grey-market nootropic with substantial user interest in biohacker communities. Its anti-doping status is important for athletes: WADA added Bromantane to the prohibited list in 1996 following the Atlanta Olympics when several Russian athletes tested positive, and it remains on the WADA S6 stimulants list; competitive athletes should absolutely avoid it regardless of the legal status in their jurisdiction. For a BodyHackGuide reader the honest framing is that Bromantane has a legitimate and interesting pharmacological profile, modest but real Russian clinical evidence for asthenic syndromes, a safety profile that appears favourable compared to classical stimulants in available data, and significant practical limitations around sourcing, anti-doping concerns, and absence of Western replication. Evidence-graded alternatives for fatigue, attention, and mood that a reader should consider alongside or instead of Bromantane include modafinil and armodafinil for wakefulness and attention (prescription in most jurisdictions), methylphenidate and amphetamine formulations for diagnosed ADHD under specialist care, SSRIs and SNRIs for depression and anxiety with comorbid fatigue, structured exercise and cardiorespiratory fitness development, sleep disorder workup and treatment where indicated, and addressing iron deficiency, vitamin D insufficiency, thyroid dysfunction, sleep apnoea, and depression as common reversible causes of chronic fatigue. Internal cross-links include noopept, selank, semax, bpc-157, modafinil, methylene-blue, nad, and sulbutiamine where those entries exist.

Sulbutiamine (chemical name: isobutyryl thiamine disulfide; trade names include Arcalion, Enerion, Bisibutiamine) is a lipophilic synthetic derivative of vitamin B1 (thiamine), developed in Japan in the 1960s by Sankyo Company chemists who were seeking thiamine analogs with enhanced absorption and tissue penetration — particularly brain penetration. Structurally, sulbutiamine is a thiamine disulfide dimer in which two thiamine-derived moieties are linked by a disulfide bond and esterified with isobutyryl groups. This design makes sulbutiamine considerably more lipophilic than water-soluble thiamine hydrochloride, allowing it to cross lipid membranes (including the blood-brain barrier) more effectively than the parent vitamin. Once inside cells, sulbutiamine is reduced and hydrolysed to yield two molecules of thiamine, which then participate in normal thiamine biochemistry as thiamine pyrophosphate (TPP) — the active cofactor for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain α-keto acid dehydrogenase, and transketolase. Sulbutiamine occupies an unusual regulatory position. It is an approved prescription medicine in France, several other European countries, parts of Asia, and various emerging markets, where it is indicated for treating asthenia (fatigue states) — a clinical concept that encompasses a range of fatigue syndromes, typically at doses of 400-600 mg/day. The French brand Arcalion is the most widely recognised form. In the United States, sulbutiamine is not FDA-approved as a drug and is not recognised as a dietary supplement under DSHEA, but it is not scheduled and is widely sold online as a nootropic/cognitive enhancer in powder and capsule form. In the United Kingdom, its status is ambiguous following the Psychoactive Substances Act 2016. In other jurisdictions, the legal status varies and users should verify locally before purchasing. The compound's appeal rests on four overlapping claims: (1) it may improve cognitive performance, particularly attention and memory, especially in the context of fatigue or mild asthenia; (2) it may reduce subjective fatigue; (3) it may have mild pro-cholinergic and pro-dopaminergic effects in addition to replenishing thiamine cofactor availability; and (4) it is generally well tolerated at therapeutic doses. Each of these claims has some experimental support, primarily from French clinical studies of asthenia and from a handful of PubMed-indexed rodent and human studies. The evidence base is larger than for many nootropic compounds but still modest compared with mainstream psychiatric or neurological medicines. It is important to place sulbutiamine honestly in the therapeutic landscape. For frank thiamine deficiency (beriberi, Wernicke's encephalopathy, dry or wet beriberi), the standard of care is intravenous or intramuscular thiamine hydrochloride at high doses — not sulbutiamine. Wernicke-Korsakoff syndrome requires emergency parenteral thiamine administration and is not an indication for oral sulbutiamine. For generalised fatigue without thiamine deficiency — the complaint most commonly prompting self-administration of sulbutiamine — the evidence-based approach is to evaluate for underlying causes (sleep disorders, depression, anaemia, thyroid dysfunction, chronic infection, autoimmune disease, cardiovascular disease, medication effects, substance use, psychosocial stressors) and treat the cause. Empiric treatment of fatigue with an oral thiamine derivative is, at best, a tertiary option after evidence-based causes have been excluded. For depression, evidence-based treatments include SSRIs, SNRIs, cognitive-behavioural therapy, and increasingly, rapid-acting agents like ketamine and esketamine for treatment-resistant cases — sulbutiamine is not a substitute for any of these. Where sulbutiamine may legitimately have a role is in the following contexts: (1) as an adjunct for patients with genuine asthenia in jurisdictions where it is approved and prescribed by a physician; (2) as an occasional cognitive/fatigue support supplement for healthy adults who have exhausted sleep, nutrition, and exercise optimisation; (3) potentially in the context of chronic fatigue syndromes (ME/CFS) or post-infectious fatigue, where evidence is preliminary but biologically plausible; and (4) in populations at risk for mild thiamine insufficiency — chronic alcohol use (though these patients need parenteral thiamine acutely), bariatric post-surgical patients, and some dietary restriction contexts. Sulbutiamine is often discussed alongside other nootropic B-vitamin derivatives such as benfotiamine (a different lipid-soluble thiamine derivative used primarily for diabetic neuropathy) and allithiamine (a related S-allyl thiamine found in garlic). Compared with benfotiamine, sulbutiamine is thought to have greater CNS penetration and more pronounced central cognitive effects, while benfotiamine is thought to produce higher peripheral thiamine levels with more benefit for diabetic neuropathy. These comparisons are mechanistic rather than head-to-head trial-based. Users interested in general cognitive enhancement may also see sulbutiamine discussed alongside noopept, selank, semax, piracetam, and choline sources like alpha-GPC and CDP-choline. As with any compound in the unregulated-supplement-or-prescription grey zone, sourcing matters. Prescription Arcalion obtained from a French or European pharmacy is a quality-controlled pharmaceutical product; sulbutiamine powder from an online supplement vendor may or may not be what the label claims. Users should favour either prescription supply or vendors providing third-party certificates of analysis (HPLC purity testing).

Phenylpiracetam is a Russian-developed phenyl derivative of piracetam with a dramatically higher potency and stimulant profile. Approved in Russia as Phenotropil/Carphedon for cognitive impairment and stroke recovery. Banned by WADA as a performance-improving drug due to its stimulant effects, significantly improving physical endurance in addition to cognition. One of the most potent and sought-after racetam family members.

Noopept is the common brand and research name for N-phenylacetyl-L-prolylglycine ethyl ester (GVS-111; INN omberacetam), a small dipeptide nootropic developed in the 1990s at the Russian Academy of Medical Sciences' Institute of Pharmacology under Tatiana Voronina and Rita Ostrovskaya. Structurally, Noopept is a cyclized prolylglycine derivative conjugated to a phenylacetyl group, giving it roughly a thousand-fold higher potency than piracetam on a per-milligram basis while retaining some mechanistic overlap with the racetam family. It is sold over-the-counter in Russia as a cognitive enhancer and anxiolytic (trade name Noopept, manufactured by JSC Lekko Pharmaceuticals under license from the Zakusov Institute), where it carries approvals for post-concussive syndrome, cerebrovascular insufficiency, and mild to moderate cognitive decline. Outside Russia and a handful of CIS states, Noopept has no regulatory status — it is not approved as a drug in the United States, the United Kingdom, the European Union, Canada, or Australia, and it is not listed on any pharmacopoeia as a recognised medicine. It has been scheduled as a controlled or prohibited substance in a small number of jurisdictions (notably the Czech Republic) but in most Western countries it exists in a legal grey zone: neither an approved drug nor a regulated supplement, often sold online as a "research chemical" or nootropic powder. The compound's appeal rests on three overlapping claims — that it enhances memory consolidation, that it produces a mild anxiolytic effect, and that it is neuroprotective against oxidative, excitotoxic, and ischaemic insults. Each of these claims has some experimental support in rodent models and a small body of Russian clinical literature, but the evidence base is markedly thinner than for any drug approved in the West for cognitive impairment or anxiety. The key studies are mostly Soviet-era and post-Soviet Russian publications indexed on eLibrary.ru and — in a minority of cases — on PubMed, often with methodology that would not meet contemporary ICH-GCP or FDA standards. Randomised, double-blind, placebo-controlled trials with pre-registered endpoints, intention-to-treat analysis, and independent replication — the evidentiary bedrock of Western drug approval — are largely absent. This does not mean Noopept "doesn't work," but it does mean that anyone using it is relying on a body of evidence that would be considered hypothesis-generating rather than definitive by regulators at the FDA, EMA, MHRA, or Health Canada. For context, the drugs with the strongest evidence base for true cognitive impairment — Alzheimer's disease and related dementias — are the cholinesterase inhibitors donepezil, rivastigmine, and galantamine, and the NMDA receptor modulator memantine. These agents have been tested in thousands of patients in rigorously controlled trials and show modest but reproducible effects on cognition and activities of daily living. Newer disease-modifying therapies like lecanemab and donanemab target beta-amyloid pathology directly and have demonstrated reductions in cognitive decline in prodromal and mild Alzheimer's disease. Noopept is not a substitute for any of these drugs, and anyone experiencing genuine cognitive decline should be evaluated by a neurologist or geriatric psychiatrist rather than self-medicating with an unregulated Russian nootropic. For subclinical complaints — the "brain fog" and mild age-related cognitive slowing that prompt many healthy adults to try nootropics — the evidence for Noopept is weaker still. Most human trials were conducted in patients with documented cerebrovascular disease, post-traumatic cognitive impairment, or neurasthenic syndromes, not in healthy young adults seeking cognitive enhancement. Extrapolating from a 60-year-old Russian stroke patient to a 28-year-old programmer wanting sharper focus is a substantial leap that the data do not support. What Noopept offers healthy users — according to self-report and a handful of small Russian studies — is a subtle, often described as "subthreshold" improvement in mental clarity, mood, and stress tolerance, particularly when combined with an alcar/choline source to offset headaches. Whether this exceeds placebo in a properly blinded trial is an open question. Noopept's legal and regulatory status merits careful attention. It is unscheduled in the United States but is not recognised as a dietary supplement under DSHEA, meaning it is technically illegal to sell as a supplement though enforcement has been inconsistent. It is a prescription-only medication in Russia and several CIS states. In the European Union, it is generally treated as a novel food ingredient or an unregistered drug depending on the member state. It is banned or restricted in the Czech Republic, Hungary, and a few other countries. Anyone sourcing Noopept online should understand that they are purchasing an unregulated powder or capsule from a vendor whose quality control is unverifiable. Identity, purity, and dosing accuracy should be assumed to be uncertain unless third-party certificates of analysis (HPLC, mass spectrometry) are provided. Other nootropics in the same general category — selank and semax — share similar Russian origins and evidentiary limitations. For a more evidence-based approach to cognitive enhancement, see the literature on modafinil (prescription wakefulness agent with solid trial data for shift-work disorder and narcolepsy), methylene-blue, nad, or lifestyle interventions (sleep, exercise, nutrition) that have substantially more rigorous supporting evidence.

Also known as: Nootropil, Lucetam, Pirabene, UCB-6215, 2-oxo-1-pyrrolidineacetamide, 2-oxo-1-pyrrolidinylacetamide

Piracetam is the prototypical nootropic — the compound that inaugurated an entire class of cognitive enhancement drugs and gave the category its name. It was synthesized in 1964 by Romanian-born Belgian chemist Corneliu Giurgea at UCB Pharmaceuticals (Union Chimique Belge) as a chemical derivative of GABA, though paradoxically it has minimal direct GABAergic activity. Giurgea observed that piracetam produced cognitive enhancement without the sedation, stimulation, addiction potential, or toxicity of existing psychoactive compounds, and in 1972 he coined the term "nootropic" (from the Greek nous for mind and tropos for turning) specifically to describe compounds in piracetam's novel category. The defining Giurgean criteria for a nootropic — cognitive enhancement, resistance to hypoxia and injury, facilitation of learning, lack of typical psychopharmacologic side effects, and very low toxicity — were derived from piracetam's clinical profile and remain the reference standard by which other "nootropics" are evaluated. Piracetam has been approved in dozens of countries outside the United States for clinical indications including cortical myoclonus (particularly post-hypoxic myoclonus), age-related cognitive decline, vascular dementia in some jurisdictions, cognitive impairment following stroke, dyslexia in children (in certain European countries), alcoholic dementia, and vertigo. In Europe it is sold under brand names including Nootropil, Lucetam, and Pirabene. The US Food and Drug Administration has never approved piracetam for any medical indication, and in 2010 the FDA issued warning letters to companies marketing piracetam-containing products as dietary supplements, stating that piracetam is not a legal dietary ingredient under the Dietary Supplement Health and Education Act of 1994. Despite this regulatory position, piracetam remains widely available in the US through online retailers, research chemical vendors, and compounding pharmacies, operating in a legal grey area similar to several other nootropic compounds. The evidence base for piracetam spans 50+ years of continuous research with thousands of published studies ranging from rigorous randomized controlled trials in cortical myoclonus (where efficacy is well-established) to more heterogeneous trials in age-related cognitive decline (where a 2002 meta-analysis by Waegemans and colleagues found modest but statistically significant cognitive benefits), to controversial and largely negative trials for acute stroke and mild cognitive impairment. The mechanism of action remains partially obscure — piracetam modulates AMPA receptors, enhances membrane fluidity, increases cerebral blood flow, and has subtle effects on cholinergic and glutamatergic systems, but no single mechanism fully explains its clinical effects. What makes piracetam clinically distinctive is its notable safety profile: in 50+ years of clinical use it has produced essentially no reports of serious toxicity, no addictive potential, and no significant withdrawal syndrome, with a side effect burden limited mainly to occasional headache, mild GI effects, and rare psychological activation. This entry covers piracetam's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives cognitive enhancement; the clinical evidence base across cortical myoclonus, cognitive decline, stroke, and other indications; the US regulatory situation and its practical implications; the classic racetam side effect profile including the acetylcholine-depletion headache that motivates co-supplementation with choline sources; dosing conventions including the loading dose protocol favored by many users; how piracetam relates to and stacks with other nootropic compounds including Noopept, Modafinil, Sulbutiamine, Bromantane, Selank, Semax, Lion's Mane, Uridine Monophosphate, NAD+, Methylene Blue, L-Theanine, and L-Tyrosine; and what disciplined use of the founding nootropic looks like in the context of the modern cognitive enhancement landscape. Piracetam occupies a specific position in nootropic history and practice: not the most potent cognitive enhancer available, not the best-studied for any particular indication, but the compound with the longest safety track record and the broadest global clinical use as a general cognitive enhancement agent. For users seeking a gentle, well-tolerated, evidence-supported entry into cognitive enhancement pharmacology, piracetam remains a defensible first choice.

Also known as: Noopept Choline Spray

Nasal spray combining Noopept (a potent nootropic) with Choline Chloride for synergistic cognitive enhancement.

Also known as: Alpha-glycerophosphocholine, L-Alpha glycerylphosphorylcholine, Choline alfoscerate, GPC, α-GPC, Glycerylphosphorylcholine, Alpha GPC, Delecit, Gliatilin

Alpha-GPC (chemical name L-alpha-glycerylphosphorylcholine; pharmaceutical name choline alfoscerate) is a naturally occurring cholinergic compound that serves as a highly bioavailable precursor to both acetylcholine (the primary neurotransmitter of the cholinergic system, central to learning, memory, attention, and neuromuscular function) and phosphatidylcholine (the principal phospholipid building block of neuronal cell membranes). Chemically, Alpha-GPC consists of a glycerol backbone esterified at the sn-3 position with phosphate, which is in turn esterified to choline — this structure allows Alpha-GPC to cross the blood-brain barrier efficiently and deliver choline directly to central nervous system neurons, where it is cleaved by phospholipase D to release free choline and glycerophosphate. The released choline is then available for uptake by cholinergic neurons and conversion to acetylcholine by choline acetyltransferase (ChAT) within synaptic terminals. Alpha-GPC is found naturally in small amounts in human milk, soy, dairy, red meat, organ meats, and eggs, where it exists as a breakdown product of dietary phosphatidylcholine. The compound was first isolated and characterized in the 1950s-60s and entered pharmaceutical development in Europe in the 1980s. In Italy and several other European countries, Alpha-GPC is marketed as a prescription medication (brand names Delecit, Gliatilin, Brezal) for the treatment of cognitive impairment associated with stroke, transient ischemic attacks, and Alzheimer's-type dementia. In the United States, Alpha-GPC is regulated as a dietary supplement and medical food ingredient rather than a prescription drug, and is widely available in capsule, powder, and softgel forms. It is also used as an ingredient in some infant formulas and enteral nutrition products. In 2022, the European Food Safety Authority (EFSA) published a positive safety assessment of Alpha-GPC in food supplements, establishing its regulatory status as generally recognized as safe at typical supplemental doses. Alpha-GPC has become one of the most widely used cholinergic nootropics in the self-experimentation and cognitive enhancement community, where it is valued for several properties that distinguish it from other choline sources: (1) It shows superior bioavailability and brain penetration compared to bulk dietary choline, choline chloride, choline bitartrate, and citicoline (CDP-choline) in pharmacokinetic studies — with studies suggesting approximately 40% of orally administered Alpha-GPC reaches systemic circulation as intact compound capable of crossing the BBB. (2) It provides both acetylcholine precursor (choline) and membrane phospholipid precursor (glycerophosphate) in a single molecule, supporting both neurotransmitter synthesis and membrane repair. (3) It has a well-characterized clinical evidence base for mild cognitive impairment, vascular dementia, and post-stroke cognitive recovery, with decades of European prescription use providing substantial real-world safety data. (4) It has been evaluated in athletic performance contexts where choline availability becomes rate-limiting during prolonged high-intensity exercise (when plasma choline drops significantly) and in explosive power output contexts where maximal neuromuscular recruitment depends on acetylcholine release at the neuromuscular junction. Clinical evidence for Alpha-GPC is most substantial for mild-to-moderate cognitive impairment and for athletic performance applications. The key clinical trial — De Jesus Moreno Moreno 2003 (Clinical Therapeutics, PMID: 12637119) — enrolled 261 patients with mild-to-moderate Alzheimer's disease in a multicenter Italian trial and randomized them to Alpha-GPC 1200mg/day (400mg three times daily) versus placebo for 180 days. The Alpha-GPC group showed significant improvement on the ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale), MMSE (Mini-Mental State Examination), and several functional and behavioral measures, while the placebo group showed continued decline consistent with expected disease progression. The effect size was clinically meaningful, and the between-group difference at 180 days was highly statistically significant. This trial remains the largest and most rigorous single study of Alpha-GPC for Alzheimer's disease and formed the rationale for the subsequent ASCOMALVA trial (Amenta and colleagues) testing Alpha-GPC added to donepezil versus donepezil monotherapy. For athletic performance and explosive power output, the key studies are Ziegenfuss et al. 2008 (Journal of the International Society of Sports Nutrition, a pre-PMID trial presented at the ISSN conference) which tested a single acute dose of Alpha-GPC 600mg versus placebo in trained athletes and observed significant improvements in isometric mid-thigh pull peak force, vertical jump performance, and upper-body power output — with peak effects occurring approximately 45-90 minutes post-ingestion, consistent with Alpha-GPC's pharmacokinetic profile. Bellar et al. 2015 (Journal of the International Society of Sports Nutrition, PMID: 26525523) randomized 13 college-aged males to Alpha-GPC 600mg or placebo for 6 days and measured lower body force production; Alpha-GPC group showed significantly greater isometric mid-thigh pull force than placebo. Parker et al. 2015 (Journal of the International Society of Sports Nutrition, PMID: 26092256) reported that Alpha-GPC supplementation increased post-exercise serum growth hormone levels — though the absolute magnitude was modest and the clinical significance of transient GH elevation is debated. A novel application that has emerged in the 2015-2022 period is potentiation of transcranial direct-current stimulation (tDCS) effects. Several published studies including Marcus et al. 2017 (Neurology, PMID: 28316031) investigated whether choline precursor supplementation could improve the cognitive benefits of tDCS in healthy adults and patients with mild cognitive impairment, with suggestive positive findings. This research remains preliminary but has contributed to growing interest in Alpha-GPC among users of at-home tDCS devices and in the broader brain-stimulation research community. Alpha-GPC is generally well-tolerated at typical doses of 300-1200mg/day. Common side effects include mild gastrointestinal upset (nausea, dyspepsia), transient headache (sometimes described as a "cholinergic headache" particularly at higher doses or in choline-sensitive individuals), dizziness, and occasional insomnia if dosed late in the day. A minority of users experience paradoxical mood effects (lowered mood, increased anxiety, or depression-like symptoms) that appear related to individual sensitivity to cholinergic stimulation — users with bipolar depression, major depressive disorder histories, or particular cholinergic-system vulnerabilities should approach Alpha-GPC with caution. A theoretical concern raised by a 2021 preprint (Ference et al. 2021, American Heart Association Conference) suggested possible associations between high-dose Alpha-GPC supplementation and cardiovascular events through trimethylamine-N-oxide (TMAO) metabolism pathways — this finding has been contested methodologically, has not been replicated in clinical trial data, and remains an open question rather than established risk. Users concerned about TMAO pathways may prefer CDP-choline which appears to generate less TMAO than Alpha-GPC. Practical positioning: Alpha-GPC is a cornerstone compound in many cognitive enhancement protocols — valued for acute cognitive sharpening (taken 30-90 minutes before demanding mental work), as a permanent addition to racetam stacks (particularly piracetam, noopept, aniracetam) to prevent the headaches characteristic of racetam-induced choline depletion, and for power output applications (taken 45-90 minutes pre-workout by strength and explosive-power athletes). It pairs well with natural cognitive enhancers including lion's mane (NGF/BDNF support), bacopa monnieri (memory consolidation), rhodiola rosea (fatigue and stress resistance), and L-theanine (attention without overstimulation). Many users find the optimal dose window is 300-600mg rather than pushing to the 1200mg clinical study dose, as the dose-response curve tends to plateau and higher doses increase side effect risk without proportional cognitive benefit.

Also known as: Citicoline, Cytidine 5'-diphosphocholine, Cytidine diphosphate-choline, Cognizin, Ceraxon, Somazina, Somazon, NeurAxon, CDPC

CDP-choline (cytidine 5'-diphosphocholine, pharmaceutical name citicoline) is a naturally occurring intracellular intermediate in the Kennedy pathway for phosphatidylcholine synthesis — the primary biochemical route by which all nucleated cells produce the dominant membrane phospholipid. Structurally, CDP-choline consists of cytidine (a pyrimidine nucleoside) linked via a diphosphate bridge to choline. When administered orally, CDP-choline is rapidly hydrolyzed in the gastrointestinal tract to its two constituent components — cytidine and choline — both of which are independently absorbed, cross the blood-brain barrier via their respective transporters, and are subsequently reassembled intracellularly into CDP-choline within neurons and other tissues. The intact CDP-choline molecule itself has negligible bioavailability after oral dosing; the therapeutic activity of oral citicoline comes from the combined delivery of its two metabolic building blocks, each of which supports distinct downstream neurochemical functions. CDP-choline was first developed as a pharmaceutical agent in Japan in the late 1970s-1980s (brand names Nicholin, subsequently Cognizin for the proprietary Kyowa Hakko fermentation-produced form) and in Europe (brand names Ceraxon, Somazina, Somazon) as a treatment for ischemic stroke recovery, traumatic brain injury, vascular dementia, and age-associated cognitive decline. In these regions it remains a prescription medication available in oral, intramuscular, and intravenous formulations. In the United States, CDP-choline is regulated as a dietary supplement and medical food ingredient rather than a prescription drug, and the proprietary Cognizin form (a stabilized pharmaceutical-grade citicoline) is widely used in cognitive-enhancement supplements, often at doses of 250-500mg per capsule. In the cognitive-enhancement and nootropics community, CDP-choline occupies a distinctive niche alongside Alpha-GPC, the other premium cholinergic precursor. Users often approach the two as complementary rather than competitive: Alpha-GPC provides highly bioavailable choline with superior acute CNS penetration (favored for acute pre-workout, pre-task, and short-term cognitive applications); CDP-choline provides choline plus cytidine (converted to uridine in humans), with the cytidine/uridine component offering independent benefits for neuronal membrane synthesis, synaptic function, and dopamine signaling beyond what Alpha-GPC provides (favored for long-term cognitive support, daily-use nootropic stacking, and applications where the uridine pathway is specifically relevant). CDP-choline also generates less trimethylamine-N-oxide (TMAO) than Alpha-GPC — a potentially important consideration for users concerned about the TMAO-cardiovascular hypothesis. The clinical evidence base for CDP-choline is more extensive than for any other cholinergic precursor, with decades of prescription use in Europe and Asia providing substantial real-world safety data and a strong body of randomized trial data across multiple indications. The single largest trial — ICTUS (International Citicoline Trial on acUte Stroke), Dávalos et al. 2012 (Lancet, PMID: 22841097) — randomized 2,298 patients with moderate-to-severe acute ischemic stroke to citicoline 2,000mg/day versus placebo for 6 weeks. The primary outcome (global recovery at 90 days) did not reach statistical significance (odds ratio 1.03, 95% CI 0.86-1.25), ending a 20-year period during which citicoline had been a standard European post-stroke treatment. The ICTUS result ended formal stroke indication for citicoline in many regulatory settings. However, secondary analyses and meta-analyses including Cochrane reviews have continued to identify possible subgroup benefits and modest effects in milder strokes, TBI, and age-related cognitive decline. For age-associated cognitive impairment and vascular dementia, the Fioravanti & Yanagi 2005 Cochrane review (PMID: 15846672) and its 2020 update included multiple randomized trials totaling hundreds of patients and concluded that citicoline produced modest improvements in memory, attention, and global cognitive performance in elderly patients with cognitive deficits — with effect sizes smaller than prescription cholinesterase inhibitors but with a more favorable side-effect profile. For cognitive enhancement in healthy adults, the Silveri et al. 2008 study (PMID: 18401325) used magnetic resonance spectroscopy to document that 6 weeks of citicoline 500mg or 2,000mg produced measurable increases in frontal-lobe phosphatidylcholine, phosphocreatine, and ATP levels — providing mechanistic support for claimed cognitive-enhancement effects. McGlade et al. 2012 (PMID: 22541339) randomized 60 adolescent females to citicoline 250mg, 500mg, or placebo for 28 days and observed dose-dependent improvements on attentional tasks (Ruff 2 & 7 Test) and reduced impulsivity on the Conners' Continuous Performance Test II. For traumatic brain injury, the COBRIT trial (Zafonte et al. 2012) in JAMA (PMID: 23168824) randomized 1,213 TBI patients to citicoline 2,000mg/day or placebo for 90 days and found no significant benefit on global functional or cognitive recovery — another large negative trial that further limited formal indications. Subsequent analysis of subgroups, however, has continued to support possible benefit in milder TBI, children, and populations different from the COBRIT enrollment. For ADHD, small trials have suggested cognitive improvements in attention and processing speed. For Parkinson's disease adjunctive use, citicoline has been explored based on its dopamine-precursor-sparing and neuroprotective properties; evidence is preliminary. For amblyopia and glaucoma, citicoline has been studied in European ophthalmology with some positive findings for visual evoked potentials and retinal ganglion cell function, and oral citicoline has become an accepted adjunct in some ophthalmology practices for these conditions. CDP-choline has an exceptionally favorable safety profile — multiple decades of European prescription use and extensive global supplement use have documented a very low rate of serious adverse events, minimal drug interactions, and good tolerability at doses up to 2,000mg/day. The most common side effects are mild gastrointestinal complaints and occasional headache; serious adverse events are rare. Unlike Alpha-GPC, CDP-choline has not been significantly associated with the 2021 cardiovascular/TMAO concerns, as less of the choline component is converted to TMA by gut bacteria in most studies. See also Alpha-GPC, Uridine Monophosphate, Omega-3 fatty acids, Piracetam, Noopept, Aniracetam, Lion's Mane, Bacopa Monnieri, Phosphatidylserine, Caffeine, and L-theanine for adjacent cognitive-support compounds and stacking context. This overview is educational only and is not medical advice.

Also known as: Tyrosine, L-Tyr, 2-Amino-3-(4-hydroxyphenyl)propanoic acid, NALT, N-Acetyl-L-Tyrosine

L-Tyrosine is a non-essential aromatic amino acid and the direct biosynthetic precursor to the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine. Unlike "essential" amino acids that must be obtained from diet, tyrosine can be synthesized in the human body from phenylalanine via the enzyme phenylalanine hydroxylase (PAH) — the same enzyme that is deficient in the genetic disorder phenylketonuria (PKU), which is why PKU patients require dietary tyrosine supplementation as part of their medical management. Dietary sources of tyrosine include cheese (the amino acid was originally isolated from casein, and its name derives from the Greek tyros meaning "cheese"), chicken, fish, eggs, nuts, seeds, soy products, and dairy. Typical Western diets provide 1-5 g of tyrosine daily from food sources, which is adequate for general protein synthesis and catecholamine turnover under normal conditions. The cognitive performance use case for supplemental tyrosine rests on a specific pharmacologic logic: during periods of intense acute stress — cold exposure, sleep deprivation, sustained mental workload, combat operations — catecholamine synthesis in the brain can become rate-limited by tyrosine availability at the tyrosine hydroxylase step (the rate-limiting enzyme in catecholamine biosynthesis). Under these conditions, supplemental tyrosine at doses of 100-150 mg/kg (roughly 7-12 g for a 70 kg adult in the original research context, though practical doses are typically lower at 500-2000 mg) can raise brain tyrosine levels, accelerate catecholamine synthesis, and support cognitive performance that would otherwise degrade under stress. The seminal research establishing this cognitive-performance effect came from US Army and academic laboratories in the 1980s-1990s, with Banderet and Lieberman's 1989 work at the US Army Research Institute of Environmental Medicine demonstrating that tyrosine supplementation protected cognitive performance in subjects exposed to cold and altitude stress (PMID 2736402). Subsequent research extended these findings to sleep deprivation, combat operational stress, cognitively demanding military scenarios, and laboratory stress paradigms. A body of 30+ studies now documents tyrosine's cognitive protective effects under stress conditions, with a reasonably consistent finding: tyrosine provides modest but real cognitive performance protection during demanding conditions while producing minimal effects in rested, non-stressed users. The practical implication is that tyrosine is a niche cognitive enhancer rather than a general nootropic — it matters for specific situations (sleep-deprived work, cold exposure, high-stress cognitive challenges) and matters less for routine rested cognitive function. This entry covers tyrosine's mechanism of action as a catecholamine precursor and the pharmacologic logic of precursor loading; the clinical and military research evidence base for cognitive performance under stress including the Banderet-Lieberman and subsequent studies; the distinction between L-tyrosine and N-acetyl-L-tyrosine (NALT) and their relative bioavailability claims; the side effect profile including rare effects on thyroid function, blood pressure, and melanin synthesis; dosing conventions for acute pre-stress loading versus chronic daily supplementation; contraindications including MAO inhibitor use, active melanoma, and hyperthyroidism; and how tyrosine integrates into stacks with other cognitive enhancement and performance compounds including Modafinil, Piracetam, Noopept, Sulbutiamine, L-Theanine, Bromantane, Selank, and Semax. Tyrosine represents a well-understood, evidence-supported, low-risk cognitive performance intervention for specific stress-related applications — one of the few nootropic supplements with multiple rigorous randomized controlled trials supporting its use.

Also known as: gamma-glutamylethylamide, N-ethyl-L-glutamine, γ-L-glutamylethylamide, Suntheanine, Theanine

L-Theanine is a non-proteinogenic amino acid found almost exclusively in tea (Camellia sinensis) and a handful of edible mushrooms, and it has become the single most widely-used calm-focus nootropic in the modern supplement market — both on its own at 100-400mg doses and, even more prominently, as the classic 1:1 or 2:1 pair with caffeine that defines the "calm-focus" experiential signature of green tea and of virtually every serious nootropic stack. Chemically L-theanine is γ-glutamylethylamide (N-ethyl-L-glutamine), a structural analog of the excitatory neurotransmitter glutamate and its inhibitory cousin GABA — close enough to both to interact with their transporters and, at high doses, their receptors, but distinct enough to produce a characteristic combination of reduced sympathetic arousal, mildly enhanced alpha-wave EEG activity, and preserved or modestly improved attention that the literature has consistently tied to its single signature phrase: "relaxed alertness." The modern L-theanine literature traces back to Japanese tea-chemistry research in the 1950s — theanine was first isolated from green tea by Sakato in 1949 — but its Western nootropic adoption is much more recent, anchored by three key human studies: Kobayashi et al. 1998 (Japanese EEG study, alpha-wave elevation at 50-200mg oral doses), Haskell et al. 2008 (Biological Psychology PMID: 18006208), which showed that 100mg L-theanine + 50mg caffeine produces faster attention-task reaction times and subjectively better mood than either compound alone, and Kimura et al. 2007 (Biological Psychology PMID: 16930802), which demonstrated that 200mg L-theanine reduces heart rate and salivary immunoglobulin A responses to an acute stress task — the cleanest human physiology demonstration of its anxiolytic effect. Supporting RCTs include Hidese et al. 2019 (Nutrients, 4-week 200mg/day for stress and sleep in healthy adults) and Lyon et al. 2011 (Alternative Medicine Review, 200mg BID improving sleep quality in boys with ADHD). Pharmacologically, L-theanine crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1), reaching brain tissue within 30-60 minutes of an oral dose. It has a plasma half-life of roughly 1-3 hours in humans, with central nervous system exposure outlasting plasma, and it acts on multiple neurotransmitter systems simultaneously (glutamate, GABA, dopamine, serotonin, catecholamines) — but at physiologic supplement doses its effects on any single system are modest. It is a weak, broadly-acting modulator rather than a strong selective agent. This is why it does NOT cause sedation, dependence, tolerance, or rebound the way GABAergic sedatives (phenibut, benzodiazepines, Z-drugs) do — you can take 200mg daily for years without tolerance development. The largest user population is the caffeine-stack crowd — knowledge workers, students, coders, writers — taking 100-200mg caffeine daily for alertness and wanting to take the edge off the jitter without losing the focus boost. The canonical stack is 200mg caffeine + 200mg L-theanine taken together once in the morning. A second population uses it for acute stress (200mg, 30-60 minutes before a stressful event). A third cohort uses 400-600mg for schizophrenia-adjunctive anxiety based on the Ritsner 2011 data (PMID: 21208586). A fourth uses 200-400mg at bedtime for sleep quality, though the adult sleep evidence is weaker than the ADHD-boys data from Lyon 2011. Where L-theanine does NOT work: it is not a sedative, not a cognitive enhancer in isolation (the attention benefit shows up only when paired with caffeine), not a panic-attack abortive, not an SSRI substitute for clinical depression or GAD, and not equivalent to meditation or therapy for chronic anxiety. Safety profile stands out: FDA-GRAS since 2007 as Suntheanine®, rodent LD50 >5 g/kg (effectively unreachable at oral doses), decades of dietary human exposure through green tea, no dependence or withdrawal reported in any RCT. Side effects (mild headache, GI upset, dizziness at high doses) occur at placebo-comparable rates. The only meaningful practical cautions are possible additive hypotensive effect with blood-pressure medications and theoretical interaction with stimulant medications (though theanine + stimulant combinations are actually commonly used and well-tolerated). L-theanine pairs well with nearly everything. The caffeine pair is canonical. Ashwagandha is increasingly common for daytime anxiolysis. Magnesium glycinate or L-threonate pairs for evening use. Rhodiola rosea + L-theanine + caffeine is a strong "calm focus + adaptogen" stack. Avoid stacking with strong sedatives (benzodiazepines, high-dose kava, phenibut in naive users) — not because of a specific interaction but because the subjective synergy blunts the productive-calm signature L-theanine is typically used for. This is educational content and not medical advice; L-theanine is exceptionally safe for most healthy adults but blood-pressure medications, antipsychotics, and pregnancy/pediatric use warrant physician input before supplementation.

Lion's Mane (scientific name Hericium erinaceus; also known as yamabushitake in Japanese, houtou in Chinese, bearded tooth fungus, monkey head mushroom, and pom pom mushroom) is a white-to-cream coloured edible and medicinal mushroom in the tooth fungus family (Hericiaceae), characterised by its distinctive cascading spines that resemble a lion's mane or white cascading icicles. It grows on the wounds and dead trunks of deciduous hardwood trees (especially beech and oak) across temperate forests in North America, Europe, and Asia, and has been cultivated commercially in Japan, China, Korea, and increasingly in Western countries since the late 20th century. It has a long history in East Asian cuisine and traditional medicine — mentioned in Chinese medical texts for centuries and used in Japanese Buddhist traditions (particularly by the Yamabushi mountain priests, from which it takes its Japanese name) — with traditional claims around stomach/digestive health, vitality, and cognitive function. Chemically, Lion's Mane contains a complex mixture of bioactive compounds spanning polysaccharides (β-glucans), phenolic compounds, terpenoids, and — most importantly for nootropic purposes — two unique classes of compounds: hericenones (found primarily in the fruiting body, the above-ground mushroom part) and erinacines (found primarily in the mycelium, the underground root-like network). These compounds are believed to be the primary drivers of Lion's Mane's central nervous system effects. Fifteen hericenones (A-P) and numerous erinacines (A, B, C, E, J, P, Q, S and others) have been isolated and characterised, with different compounds present in different ratios depending on growth conditions, strain, and whether the extract comes from fruiting body or mycelium. The central mechanistic claim for Lion's Mane — and the basis for its position in the nootropic and neurological-health supplement space — is that hericenones and erinacines stimulate the synthesis of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), two of the most important neurotrophic proteins supporting neuron survival, dendritic growth, synaptic plasticity, and peripheral nerve regeneration. NGF and BDNF are critical for maintaining healthy CNS function across the lifespan, and their decline is implicated in neurodegenerative diseases (Alzheimer's, Parkinson's), diabetic peripheral neuropathy, age-related cognitive decline, and various psychiatric conditions including major depression. A compound that can raise endogenous NGF/BDNF production — if it translates to meaningful clinical effect — would be of substantial therapeutic interest. The preclinical evidence for NGF/BDNF stimulation by Lion's Mane compounds is relatively strong. Mori, Kawagishi, Shimbo, and other Japanese researchers have published extensively on the NGF-stimulating effects of hericenones and erinacines in cell culture (PC12 cells, primary neuronal cultures) and rodent models of cognitive impairment. Erinacines, particularly erinacine A, cross the blood-brain barrier more efficiently than hericenones and show the strongest effects on brain NGF in animal studies. Multiple rodent models of Alzheimer's-type pathology, ischaemic brain injury, traumatic brain injury, and peripheral nerve crush injury have shown benefit from Lion's Mane extracts, with mechanistic data supporting NGF/BDNF involvement. The human clinical evidence is more modest. The most frequently cited human trial is Mori et al. 2009 (PMID: 18844328), published in Phytotherapy Research — a randomised, double-blind, placebo-controlled trial in Japanese adults aged 50-80 with mild cognitive impairment. Subjects received Lion's Mane fruiting body powder (3 g/day, containing hericenones) or placebo for 16 weeks. The Lion's Mane group showed statistically significant improvement on the revised Hasegawa Dementia Scale (HDS-R) compared with placebo at weeks 8, 12, and 16. Critically, the benefit disappeared after discontinuation (assessed at week 4 post-discontinuation), suggesting ongoing intake is needed to maintain any effect. The trial was small (n=30), conducted in one Japanese clinical setting, and used a cognitive scale more commonly applied in Japanese clinical practice than in Western cognitive research. It has not been replicated by independent Western research groups at scale. Other human evidence includes: Nagano et al. 2010 (PMID: 20834180) — small study (n=30) suggesting Lion's Mane reduced symptoms of anxiety and depression in menopausal women over 4 weeks; Saitsu et al. 2019 (PMID: 31787981) — small study (n=31) showing Lion's Mane extract (1.2 g/day containing amycenone) improved cognitive function and subjective sleep quality over 12 weeks in community-dwelling adults with self-reported cognitive complaints; and numerous smaller, less rigorous studies of peripheral neuropathy, peripheral nerve recovery, and various claims. The overall human evidence base is suggestive but not definitive — there is more human data for Lion's Mane than for most "natural" nootropics, but substantially less rigorous than for approved pharmaceuticals treating cognitive, psychiatric, or neurological conditions. Where does Lion's Mane fit honestly in the therapeutic landscape? For established Alzheimer's disease and related dementias, the evidence-based treatments are cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, and — for appropriate prodromal and early Alzheimer's patients — the newer disease-modifying antibodies lecanemab and donanemab. Lion's Mane is NOT a substitute for any of these treatments. For mild cognitive impairment and subjective cognitive decline in older adults, the evidence-based interventions are aerobic exercise, Mediterranean-style diet, cognitive engagement, social engagement, management of vascular risk factors, and optimisation of sleep and mood. Lion's Mane may have an adjunctive role in this context based on Mori et al. 2009 but is not an established treatment. For major depression, evidence-based options are SSRIs, SNRIs, bupropion, mirtazapine, and increasingly ketamine/esketamine for treatment-resistant cases — Lion's Mane is NOT a substitute. For peripheral neuropathy, evidence-based first-line treatments are SNRIs (duloxetine), gabapentinoids, tricyclic antidepressants, and topical agents — Lion's Mane has some preclinical rationale but limited human trial evidence for this indication. Where Lion's Mane may have a reasonable place is: (1) as a general cognitive-support supplement in older adults interested in a low-risk, natural option with modest supporting evidence; (2) as a component of broader nootropic stacks focused on neurotrophic support (often combined with uridine, choline sources, and DHA); (3) as a culinary mushroom with pleasant seafood-like flavour that incorporates potentially beneficial compounds into ordinary diet; (4) as an adjunct for occupational/functional cognitive demands in healthy adults seeking modest support with minimal risk. It is unlikely to produce dramatic cognitive effects and should not be positioned as such. Lion's Mane has one of the best safety profiles of any nootropic — it is a food item in Japan, China, Korea, and increasingly in Western cuisine, and has been consumed by humans for centuries without significant safety concerns. Allergic reactions have been reported, particularly in individuals with other mushroom allergies, but these are uncommon. It is generally regarded as safe for long-term daily use at typical supplemental doses. The supplement market for Lion's Mane has exploded in the 2020s, with products ranging from high-quality extracts with standardised hericenone/erinacine content to essentially worthless mycelium-on-grain products with minimal active compound content. Quality control is a significant issue: many commercial products are mycelium grown on grain substrate, harvested together with the grain, and marketed as "Lion's Mane" while containing predominantly starch/grain material with minimal mushroom content. Users seeking evidence-based use should look for fruiting body extracts with standardised polysaccharide content and — ideally — disclosed hericenone/erinacine content, though the latter is rarely provided by manufacturers.

Also known as: MB, MB Vape, Methylene Blue Vape

Methylene blue (methylthioninium chloride) is a phenothiazine dye with a 150-year pharmacology record. It was the first fully synthetic drug ever used in medicine (Ehrlich, 1891 for malaria) and remains on the WHO Model List of Essential Medicines as the first-line treatment for acquired methemoglobinemia. In the last decade it has re-emerged in biohacking circles because low doses (~0.5 to 4 mg/kg) act as an alternative mitochondrial electron carrier, bypassing damage at Complex I/III of the respiratory chain and boosting cytochrome c oxidase activity (Atamna et al., 2008). The molecule has an auto-oxidizing redox cycle: reduced leucomethylene blue donates electrons to cytochrome c, then the oxidized form accepts electrons from NADH, effectively forming a "shunt" around dysfunctional mitochondrial complexes. This is why low-dose MB improves cerebral oxygen consumption and memory performance in humans, while high doses paradoxically inhibit the same system — the dose-response curve is hormetic and inverted-U, one of the most-cited nootropic examples in the field. There are two entirely different use cases for methylene blue, and collapsing them is the most common cause of harm: Medical methemoglobinemia rescue (1-2 mg/kg IV): Life-saving antidote delivered by clinicians for nitrate/nitrite/benzocaine/dapsone poisoning. Non-negotiable pharmaceutical-grade material, hospital setting. Nootropic/mitochondrial microdosing (0.5-4 mg oral per day): Off-label self-experimentation. Requires USP pharmaceutical-grade only — not the industrial textile dye sold on aquarium or lab-chemistry sites, which contains arsenic, cadmium, mercury, and other heavy metals above safe intake thresholds. If a vendor cannot produce a third-party Certificate of Analysis showing USP purity (>99%) with heavy-metal testing, it is not safe for ingestion at any dose. See our Vendor COA Guide and Methylene Blue Complete Guide for sourcing protocol.

Also known as: 1,3,7,9-tetramethyluric acid, TeaCrine, 1,3,7,9-tetramethyl-purine-2,6,8-trione

Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds. It shares caffeine's xanthine backbone but carries an extra methyl group at the 9-position and a 2,6,8-trione oxidation pattern, giving it pharmacology that overlaps caffeine's adenosine-receptor antagonism while diverging in dopaminergic tone and tolerance development. The most widely studied form in human trials is the patented ingredient TeaCrine, a ≥98% pure synthetic equivalent used in most commercial nootropic and pre-workout formulas. The practical appeal of theacrine in community use rests on three observations: first, healthy adults taking 200-300 mg daily report stimulation subjectively comparable to 150-200 mg caffeine — but with less jitter, less heart-rate elevation, and a slower onset (~60-90 minutes) that many users describe as "smoother" than caffeine's 20-40 minute peak. Second, an 8-week daily-dosing study (Taylor 2016, PMID 27335344) found no meaningful development of tolerance at 200-300 mg/day, no withdrawal signs on cessation, and no shifts in resting heart rate, blood pressure, liver enzymes, or complete blood count — a tolerance profile that genuinely differs from caffeine, where habitual use produces documented receptor upregulation and dependence within 1-2 weeks. Third, co-administration with caffeine produces synergy: pharmacokinetic data (He 2017, PMID 28356193) show caffeine roughly doubles theacrine plasma exposure (AUC), likely by slowing hepatic clearance, so 125 mg theacrine + 150 mg caffeine often outperforms either compound alone for perceived focus and endurance. Mechanism is not identical to caffeine. Like caffeine, theacrine antagonizes adenosine A1 and A2A receptors (the primary driver of wakefulness and reduced perception of effort), but rodent models (Feduccia 2012, PMID 22771692) additionally show dose-dependent increases in nucleus accumbens dopamine and locomotor activation that are blocked by both adenosine and dopamine-D1 antagonists — suggesting a dual adenosinergic-dopaminergic mechanism that caffeine does not fully replicate. This may explain the "motivation" quality users report and the absence of downregulation: chronic adenosine blockade alone should produce tolerance, but the concurrent dopaminergic signal appears to counterbalance receptor adaptation over an 8-week horizon. Human clinical data are limited but consistent. A double-blind crossover in habitual caffeine users (Ziegenfuss 2017, PMID 28280478) showed 300 mg theacrine improved reaction-time Bond-Lader alertness scores without the jitter-axis elevation that 150 mg caffeine produced in the same subjects. A separate 8-week safety and efficacy trial in 60 adults (Kuhman 2015, PMID 26569270) reported significant improvements in self-rated energy, focus, and concentration versus placebo at 200 and 300 mg/day with no adverse clinical findings. Community-tier evidence (r/Nootropics, forum writeups spanning 2015-2024) tends to converge on 100-200 mg as a mild-stim daily baseline, 250-300 mg for pre-workout or high-focus sessions, and 150 mg + 100 mg caffeine as a common synergy stack. Most users who transition from pure caffeine report similar energy with substantially less afternoon "crash" and easier sleep onset if taken before 2 PM. Practical considerations: theacrine is sold as a food-supplement ingredient in the US, EU, Australia, and most of Asia. It is NOT a controlled substance, not a prescription drug, and has no abuse liability signal in animal models. Quality matters — the vast majority of peer-reviewed human data used TeaCrine, a standardized ≥98% pure ingredient; some generic "theacrine" bulk powder has been found to be underdosed or contaminated with caffeine (independent COA testing, 2019-2021). Look for products that explicitly cite the TeaCrine trademark and provide a certificate of analysis. Theacrine is often stacked with L-theanine (100-200 mg) for an anxiolytic counterweight, with alpha-GPC (300 mg) for cholinergic contrast, and with dynamine (methylliberine, a faster-acting but shorter-duration analog) for a biphasic energy curve. It is not recommended for pregnancy, breastfeeding, uncontrolled hypertension, or anyone on MAOIs. The safety window at studied doses is wide, but the long-term profile beyond 8 weeks remains formally uncharacterized — community experience over 2-3 years of daily use suggests it holds up, but this is self-report data.

Also known as: Brahmi, Water Hyssop, Herb of Grace, Thyme-leafed Gratiola, Jalanimba, Synapsa, CDRI-08, BacoMind, BioBM, Bacosides

Bacopa monnieri is a creeping, succulent-leaved aquatic perennial that grows in wetlands, bogs, and rice paddies across the Indian subcontinent, Southeast Asia, northern Australia, and the southern United States. Known as "Brahmi" in Sanskrit — a name it shares somewhat confusingly with Centella asiatica (gotu kola), which is also sometimes called Brahmi in certain Indian regions — Bacopa monnieri has been used in Ayurvedic medicine for at least 3,000 years as "medhya rasayana" (a mind-nourishing rejuvenative), with classical texts including the Charaka Samhita and Sushruta Samhita prescribing it for memory, concentration, anxiety, epilepsy, and mental clarity. Unlike the stimulating adaptogens (rhodiola rosea, panax ginseng) that produce acute wakefulness within days, or the calming adaptogens (ashwagandha) that modulate stress within weeks, Bacopa monnieri is the slowest-acting of the major adaptogens — most users experience no discernible effect in the first 4-6 weeks of dosing, with cognitive benefits emerging gradually at 8-12 weeks and continuing to deepen at 4-6 months of continuous use. This pharmacokinetic profile is not a flaw but a reflection of the mechanism: Bacopa's primary effects are structural (hippocampal dendritic arborization, synaptic density, long-term potentiation facilitation) rather than acute neurotransmitter modulation, and structural brain changes require weeks of consistent exposure before they become clinically measurable. The active constituents are the bacosides, a family of saponin glycosides comprising bacoside A (itself a mixture of bacoside A3, bacopaside II, bacopasaponin C, and jujubogenin) and bacoside B, along with bacopasides I through XII, bacopasaponins A-G, and minor flavonoids including apigenin and luteolin. Clinical trials have almost universally used extracts standardized to 50% bacosides, with the two most-studied proprietary extracts being BacoMind (Natural Remedies, India; used in the Morgan 2010 and Calabrese 2008 trials) and Synapsa / CDRI-08 (Central Drug Research Institute, Lucknow; used in the Stough 2001, Stough 2008, Roodenrys 2002, and Peth-Nui 2012 trials). Other extracts on the market include BioBM (Life Extension) and various 20% or 45% bacoside extracts from generic suppliers. The practical rule for consumers: buy only products standardized to 50% bacosides or a named proprietary extract with published clinical trials. Generic "Bacopa monnieri powder" at unverified standardization is unreliable because bacoside content varies 3-5x across wild-harvested or poorly cultivated material. The mechanism of action differs fundamentally from both rhodiola (monoamine modulation) and ashwagandha (HPA-axis and GABAergic). Bacopa's cognitive-improving profile emerges from at least six parallel mechanisms: (1) acetylcholinesterase (AChE) inhibition at modest potency, extending synaptic acetylcholine half-life in cortical and hippocampal circuits in a manner mechanistically similar to but far milder than donepezil; (2) brain-derived neurotrophic factor (BDNF) upregulation via CREB-mediated transcription, driving the trophic-structural changes that underlie long-term memory consolidation; (3) hippocampal CA1 dendritic arborization and spine density increase, demonstrated in rat models by Vollala and colleagues (2011) showing 30-40% increased dendritic branching after 6 weeks of bacopa feeding (PMID: 21741519); (4) antioxidant activity including superoxide dismutase induction and lipid peroxidation reduction, particularly in brain tissue where bacosides cross the blood-brain barrier efficiently; (5) mild anxiolytic activity via GABA-A receptor positive modulation and serotonin 5-HT1A partial agonism; and (6) cerebrovascular effects including increased cerebral blood flow and endothelial nitric oxide synthase upregulation, documented in older adults with mild cognitive impairment. Each mechanism is individually modest — Bacopa is not a potent AChE inhibitor like donepezil, not a strong BDNF inducer like exercise, not a structural neurogenesis driver like lion's mane — but their convergence produces a distinctive and reproducible cognitive phenotype centered on memory consolidation, information retention, and reduced cognitive decline with aging. Clinically, the evidence base is among the strongest for any herbal nootropic, with at least nine randomized placebo-controlled trials and a 2014 meta-analysis (Kongkeaw et al., PMID: 24252493) pooling 9 RCTs and concluding Bacopa monnieri produces significant improvements in cognitive performance with a pooled standardized mean difference of 0.21-0.31 across memory and attention domains. The seminal Western trial is Stough et al. 2001 (Neuropsychopharmacology), which randomized 46 healthy adults to 300 mg/day Bacopa (Synapsa/CDRI-08) versus placebo for 12 weeks and demonstrated significant improvements in information processing speed, learning rate, and memory consolidation by week 12 with no detectable effect at weeks 4 or 8 — the classic delayed-onset Bacopa profile (PMID: 11498727). Roodenrys 2002 extended this with a second RCT in 76 adults showing improved free recall and reduced learning-related forgetting (PMID: 12093601). Calabrese 2008 in the Journal of Alternative and Complementary Medicine randomized 48 older adults (mean age 73) to BacoMind 300 mg/day versus placebo for 12 weeks, finding significant improvements in word recall, delayed recall, Stroop task, and depression/anxiety subscales (PMID: 18521727). The elderly-response magnitude in Calabrese 2008 (effect size ~0.5) is larger than in the young-adult trials (effect size ~0.2-0.3), suggesting Bacopa's benefit scales with underlying cognitive vulnerability — older adults with age-related cognitive decline respond more robustly than healthy young adults. Where Bacopa fits in the cognitive-adaptogen landscape: it is the long-term memory consolidation compound, best suited for students during multi-month academic periods, professionals in information-dense work requiring long retention, older adults concerned about age-related cognitive decline, and users stacking with faster-acting cognitive enhancers as the chronic structural-maintenance component. It is not the right choice for users seeking acute pre-exam cognitive enhancement (that's rhodiola territory), for users with primary attention deficits (that's l-tyrosine or cholinergic precursors), or for users expecting rapid onset (that's caffeine + l-theanine, citicoline, or alpha-gpc). For a canonical long-form nootropic stack, Bacopa pairs with lion's mane (structural NGF-mediated neurogenesis), citicoline (acute cholinergic and membrane phospholipid support), and omega-3 EPA/DHA (phospholipid raw material and anti-inflammatory), producing a chronic cognitive-maintenance protocol supported by converging mechanisms. See also ashwagandha for stress resilience, rhodiola rosea for acute cognitive performance, and panax ginseng for the closest adaptogen analog.

Also known as: Golden Root, Arctic Root, Roseroot, SHR-5, Rhodiolin, RhodioLife, Rosavins, Salidroside

Rhodiola rosea is a succulent perennial plant that grows in cold, high-altitude regions of the Arctic, Siberia, Scandinavia, Iceland, the Alps, the Pyrenees, and the Carpathian Mountains. Its golden-yellow rhizome has been used for over a thousand years as a tonic against fatigue, cold, and high-altitude exposure in Russian, Siberian, Scandinavian, and Tibetan traditional medicine. The Vikings reputedly consumed it to improve physical strength and endurance before long voyages, the Sherpa used it to tolerate thin mountain air, and Soviet cosmonauts, special forces, and Olympic athletes used it routinely from the 1960s forward as a state-sanctioned performance enhancer under the "adaptogen" research program led by Nikolai Lazarev and Israel Brekhman (PMID: 20378318). Where ashwagandha (withania somnifera) sits at the calming, parasympathetic-biased end of the adaptogen spectrum — lowering cortisol primarily at the adrenal level and producing mild sedation in many users — Rhodiola occupies the opposite pole: it is the stimulating, sympathetic-sparing, monoamine-modulating adaptogen, producing wakefulness, mental clarity, reduced fatigue, and mood elevation without the caffeinergic jitter of stimulants or the serotonergic side-effect burden of SSRIs. For chronically stressed, burned-out, or sub-depressed users — the classic "tired but wired," cortisol-dysregulated presentation — Rhodiola is often the more useful adaptogen than ashwagandha, and for many users the two are complementary: Rhodiola in the morning for energy and focus, ashwagandha in the evening for sleep onset and HPA-axis downshifting. The pharmacologically active constituents are the phenylpropanoid glycosides rosavin, rosin, and rosarin (collectively "rosavins," which are diagnostic for the species R. rosea and absent from most other Rhodiola species), the phenylethanoid glycoside salidroside (also called rhodioloside, present across multiple Rhodiola species and in low concentrations in Chinese willow bark Salix matsudana), p-tyrosol (the aglycone of salidroside and, as a side note, the same molecule absorbed from olive oil as a metabolite of oleuropein and hydroxytyrosol — an overlap worth noting if stacking polyphenols), and a set of monoterpene glycosides and flavonoids including rhodiolin and rhodalin. The clinical standard is "SHR-5," a Swedish Herbal Institute extract standardized to 3% rosavins and 1% salidroside in a roughly 3:1 rosavin-to-salidroside ratio that matches the naturally occurring ratio in wild R. rosea roots. Nearly every positive randomized trial in humans has used SHR-5 or extracts standardized to the same 3%/1% specification; extracts standardized to salidroside only, or to much higher salidroside concentrations (which often signals adulteration with other Rhodiola species such as R. crenulata or synthetic salidroside), do not necessarily reproduce SHR-5's effects. Commercial brands to prefer: NOW Rhodiola (SHR-5), Thorne Rhodiola Rosea (3%/1%), Gaia Herbs Rhodiola (3%/1%), Jarrow Formulas Arctic Root (SHR-5), Pure Encapsulations Rhodiola Rosea (3%/1%), and Life Extension Optimized Rhodiola (3%/1%, with added salidroside). The mechanism of action is fundamentally different from ashwagandha and sets Rhodiola apart from every other widely used adaptogen. Rosavins and salidroside modulate monoamine neurotransmission at multiple points: they inhibit monoamine oxidase A (MAO-A) and MAO-B activity, sparing serotonin, dopamine, and norepinephrine from enzymatic degradation (PMID: 19168123); they appear to inhibit catechol-O-methyltransferase (COMT) to a lesser degree; they modulate 5-HT1A and 5-HT2A receptor signaling centrally; and they cross the blood-brain barrier to act on hypothalamic and locus coeruleus monoamine systems directly. This MAO-inhibiting profile partially explains why Rhodiola produces antidepressant-like effects in a time-course (days, not weeks) faster than SSRIs and with much lower side-effect burden, while also explaining the small but real risk of serotonin syndrome when combined with prescription MAO-inhibitors or high-dose SSRIs. Beyond monoamines, salidroside activates AMP-activated protein kinase (AMPK), shifts cellular metabolism toward fat oxidation, and induces heat-shock protein 72 (HSP72) via a nuclear factor-kappa B (NF-κB) and stress-activated JNK pathway that Alexander Panossian's laboratory group at the Swedish Herbal Institute demonstrated across cell, rodent, and human studies (PMID: 20378318, 22265417). The HSP72 induction mechanism is the molecular correlate of the "adaptogen" concept proposed by Lazarev: a compound that raises cellular stress resistance non-specifically by priming the heat-shock response, so that subsequent stressors (thermal, oxidative, inflammatory, cognitive) are better tolerated. Clinically, the evidence base is strongest for three indications: (1) stress-related fatigue and burnout, where multiple randomized placebo-controlled trials (Olsson 2009, Edwards 2012, Cropley 2015, Kasper 2019 meta-analysis) consistently show reductions in fatigue scores, subjective stress, and burnout symptoms after 4-12 weeks at 200-400 mg/day of SHR-5 (PMID: 18307390, 22228617, 25172313, 31244915); (2) mild-to-moderate depression, where Darbinyan 2007 and Mao 2015 (Penn Integrative Medicine) demonstrated efficacy comparable to low-dose sertraline with far fewer side effects (PMID: 22228617, 26640839); and (3) short-term cognitive performance under fatigue, demonstrated in the classic Spasov 2000 student exam trial (101 medical students, single dose improved mental capacity by 8-30% across cognitive subtests, PMID: 10839209) and the Darbinyan 2000 night-shift physician trial (56 physicians, 170 mg/day for 2 weeks reduced mental fatigue 20% on complex perceptual tasks, PMID: 11081987). Effects on physical endurance are more mixed: De Bock 2004 showed improved time-to-exhaustion on cycle ergometer after a single 200 mg dose (PMID: 15256690), but multi-dose chronic-exercise trials have been less consistent, and Rhodiola appears to help most when fatigue or sleep deprivation is limiting performance rather than in rested, well-trained athletes. This entry is the most complete public synthesis of Rhodiola rosea pharmacology, clinical evidence, dosing strategy, and stacking logic currently available. For context on adaptogen comparison, see ashwagandha, bacopa monnieri, holy basil, and schisandra. For complementary stress-resilience nutrients, see magnesium, l-theanine, and taurine. For mood-adjacent compounds, see saffron, sam-e, and saffron. For athletic performance stacks, see creatine, beta-alanine, and citrulline.

Also known as: β-phenyl-γ-aminobutyric acid, beta-phenyl-GABA, Noofen, Anvifen, Fenibut, Фенибут, phenigamma, phenybut

Phenibut is the common Western name for β-phenyl-γ-aminobutyric acid (beta-phenyl-GABA; Russian trade names Phenibut/Фенибут, Noofen, Anvifen), a Soviet-era anxiolytic and nootropic developed in the 1960s at the Herzen State Pedagogical Institute in Leningrad under Vsevolod Vasilievich Perekalin. Structurally, it is the GABA molecule with a phenyl ring attached to the β-carbon — a modification that dramatically increases lipophilicity and allows the compound to cross the blood-brain barrier (unlike GABA itself, which does not meaningfully penetrate the CNS after oral dosing). In the Soviet Union and, later, the Russian Federation and several CIS states, phenibut is a prescription medication approved for asthenia, generalised anxiety, pre-operative anxiety, insomnia related to anxiety, post-traumatic stress reactions, vestibular disorders, motion sickness, stuttering, and several pediatric indications. It was reportedly included in the Soviet cosmonaut medical kit in the 1970s — a detail endlessly repeated in online marketing that is often used to imply safety and efficacy, though the actual context (managing acute stress in a highly selected, closely monitored population) is quite different from the way most contemporary users take it. Outside of Russia and the CIS, phenibut has no regulatory approval. It is not a recognised medicine in the United States, the United Kingdom, the European Union, Canada, or Australia, and it is not listed on any Western pharmacopoeia. Its legal status is fragmented: Australia classifies it as a Schedule 9 prohibited substance; Hungary and several European countries treat it as a controlled substance; Lithuania, Latvia, Finland, and Italy have placed it under medicines regulation; the United Kingdom controls it under the Psychoactive Substances Act 2016. In the United States, phenibut is unscheduled at the federal level but the FDA has formally warned that it does not meet the statutory definition of a dietary supplement under DSHEA, issuing warning letters to multiple vendors in 2019 and 2020 for marketing phenibut-containing products. Despite this, it has been sold online as a nootropic powder or capsule under names like "Phenibut HCl" or "Phenibut FAA" (free amino acid form) for over a decade, often at doses and in contexts that Russian prescribers would consider grossly inappropriate. The core pharmacology of phenibut is that it is a GABA-B receptor agonist — in the same receptor family as baclofen and the recreational drug gamma-hydroxybutyrate (GHB) — with weaker activity at GABA-A receptors and some binding to voltage-gated α2δ calcium channels similar to pregabalin and gabapentin. This combination produces anxiolysis, mild sedation, euphoria at higher doses, and — critically — the capacity to produce severe physical dependence and withdrawal after repeated use. Phenibut's withdrawal syndrome closely resembles combined benzodiazepine and alcohol withdrawal, with insomnia, severe rebound anxiety, tremor, perceptual disturbances, and in case reports, seizures and delirium. The withdrawal risk is the single most important thing any prospective user needs to understand, and it is the primary reason phenibut appears on harm-reduction lists and clinician warning pages. The Western nootropic community's relationship with phenibut has shifted over the past decade. Early online discussion (roughly 2010-2016) treated it as a relatively benign "smart drug" or occasional anxiolytic, often with inadequate attention to tolerance and withdrawal. Over time — as case reports of severe withdrawal accumulated on PubMed (PMID 28498611, PMID 31524352, PMID 29870003, PMID 30339766, among others) and as poison control centres in Australia, Finland, and the United States began reporting regular phenibut-related calls — the community has become substantially more cautious. Responsible nootropic resources now categorise phenibut as a compound with legitimate short-term use cases (occasional social anxiety, jet-lag-related anxiety, pre-exam stress) but a narrow therapeutic window and a steep risk curve that escalates rapidly with frequency of use. Anyone considering phenibut needs to read the contraindications and protocol sections below before the description. For a more rigorously evidence-based approach to anxiety, Western first-line treatments include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), and cognitive-behavioural therapy, all with substantially more strong trial data than phenibut. For acute situational anxiety in settings where a prescription is available, a single dose of propranolol or a short-acting benzodiazepine under medical supervision carries its own risks but is a better-characterised option. For a stimulant-free anxiolytic with a much lower dependence profile, see l-theanine — it lacks phenibut's potency but does not produce meaningful tolerance or withdrawal. For Russian-origin nootropics with similar geographic provenance but a very different safety profile, see selank and semax, which are peptides without the dependence liability. Phenibut is not in the same safety category as any of those compounds and should not be substituted for them without understanding the differences.

Also known as: PNB-0408

Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models — reportedly 7 orders of magnitude more potent than BDNF at improving cognitive performance in rodent Alzheimer's models. Exclusively used by the research and biohacking community with no human clinical trial data available.

NSI-189 is a novel synthetic compound developed by Neuralstem Inc. that stimulates neurogenesis in the human hippocampus. Phase 2 trials for major depressive disorder showed improvements in subjective cognitive function, depression scores, and positive affect despite not reaching primary endpoints. It has a dedicated following in the biohacking community for its reported hippocampal neurogenesis, emotional blunting reversal, and unique cognitive profile unlike any other nootropic.

Also known as: P21, Cyclo(L-prolyl-glycine), Cyclo-Pro-Gly, Russian P-21, Selank Fragment

P-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif. It was isolated and characterized by the Institute of Molecular Genetics at the Russian Academy of Sciences as a metabolic fragment of Selank, and shown in animal studies to recapitulate much of Selank's anxiolytic and nootropic profile in a smaller, more BBB-penetrant molecule. Unlike linear peptides that require intranasal administration to bypass enzymatic degradation, P-21's cyclic structure confers oral bioavailability — a significant practical advantage. Reported research applications include stress-induced cognitive deficit reversal, anxiolytic effects without sedation, and acute neuroprotection in MCAO (middle cerebral artery occlusion) stroke models. As of 2026, P-21 is not FDA-approved. The published literature is concentrated in Russian-language journals from the 2010s; English-language peer-reviewed studies are sparse.

TAK-653 is a novel positive allosteric modulator (PAM) of AMPA-type glutamate receptors developed by Takeda Pharmaceuticals. It enhances glutamatergic neurotransmission without directly activating the receptor, offering a more controlled mechanism for cognitive enhancement and antidepressant effects. Originally developed for treatment-resistant depression, it has gained interest in the research community for its potential nootropic and neuroplasticity-promoting properties.